Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 2009

View Archived Issues

SK Chemicals to evaluate SID-530 and taxotere bioequivalence in a phase I trial

Novel MEK inhibitors in early development at UCB

New data on oseltamivir in H1N1 and H5N1 viruses discussed at ICAAC

In vitro, in vivo and phase I studies describe antibacterial ozenoxacin

Rib-X receives NIAID award to develop antibiotic treatment for gonorrhea

Arena reports BLOSSOM trial results for weight management

Vernalis completes recruitment in phase II V-3381 study for neuropathic pain

Zolinza approved in Canada for advanced cutaneous T-cell lymphoma

S1P1 receptor modulator BAF-312 developed as a potential new treatment for MS

Vitamin D3 analogue TEI-K04887 reduces PTH levels without causing hypercalcemia in vivo

MK-0674 reduces tumor-induced osteolysis in rabbit model of metastatic bone disease

OSI dislcoses novel protein kinase inhibitors for treating cancer

Neurogen describes novel TRPV1 modulators for the treatment of pain

New compounds for asthma therapy claimed by AstraZeneca and Argenta Discovery

Cel-Sci to begin clinical study of LEAPS-H1N1 in H1N1-infected patients

Hyperion receives orphan drug status for HPN-100 for hepatic encephalopathy

FDA Advisory Committee recommends Xiaflex approval for Dupuytren's disease

GSK provides update on pandemic (H1N1) influenza vaccine

Intarcia Therapeutics commences enrollment in phase II ITCA-650 study

KemPharm nominates candidate for treatment of pain

Sanofi-aventis receives FDA Complete Response Letter for eplivanserin

Savient provides update on meeting with FDA for Krystexxa

Pharmos reports results of phase IIb dextofisopam trial in irritable bowel syndrome

Biomoda adds longitudinal study to lung cancer phase II trial protocol

Companies validate cardiomyocyte progenitors derived from human embryonic stem cells

JTT-305 shows promise for the treatment of hypocalcemia and osteoporosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...